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Positron Emission Tomography/Computed Tomography (FDG-
PET/CT) standardized uptake value (SUV) and total lesion 
glycolysis (TLG) with tumour characteristics and clinical 
response in a series of rectal cancer patients treated with 
neoadjuvant chemo-radiotherapy 
 
Material and Methods: Fifty-six patients were included in the 
present analysis. Pre-treatment PET maximum SUV (SUVmax), 
mean SUV and TLG of primary tumour were calculated for 
each patient. The total dose of pelvic radiotherapy was 45-
50.4 Gy, 1.8 Gy/fraction. Chemotherapy was delivered with 
capecitabina or 5-fluorouracil. Six to eight weeks after RT-
CT, 44 patients (78.6%) had anterior rectal resection and 12 
patients (21.4%) had abdominal pelvic resection (Miles).  
Tumor Regression Grade (TRG) (Mandard, 1994) was defined 
on surgical specimen. Complete regression (TRG1) was 
observed in 10/56 (17.9 %).The correlation between PET/CT 
results and histopathological data and tumour response was 
analyzed.  
 
Results: At the level of the primary tumour, SUVmax ranged 
from 4.17 to 54.06 (mean 22.46, median 18.89), SUV mean 
ranged from 6.22 to 32.64 (mean 13.42, median 11.09) and 
TLG ranged from 7.96 to3158.23 (mean 350.21, median 
183.55).SUVmax (p=0.05) and TLG (p=0.002) significantly 
correlated with T-stage. Median SUVmax was significantly 
higher (p = 0.05) for lesions with partial response (PR, 46/56, 
82.1%) than for lesions with complete response (CR, 34/54, 
17.9%). Median TLG was significantly higher (p=0.034) for 
lesions with partial response (PR, 45/54, 83.3%) than for 
lesions with complete response (CR, 9/54, 16.7%). 
SUVmean was not significantly correlated with T-stage 
(p=0.074). Median SUVmean was higher for lesions with 
partial response (PR, 45/54, 83.3%) than for lesions with 
complete response (CR, 9/54, 16.7%) but without statistical 
significance (p =0.18).  
 
Conclusion: Our data suggest that pre-treatment FDG-
PET/CT SUVmax and TLG are strongly associated with tumour 
primary tumour stage. Furthermore they correlate with 
prediction of tumour response after neoadjuvant treatment 
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Purpose or Objective: To evaluate pathological response and 
clinical outcomes in women with locally advanced cervical 
cancer treated with radiochemotherapy and surgery in a 
tertiary hospital. 
 
Material and Methods: In this retrospective analysis we have 
included 59 patients with cervical cancer (FIGO stages IB2-
IVA) who were treated between December 2004 and July 
2015 with concurrent chemoradiation therapy (CCRT) 
followed by surgery. The patients were treated with pelvic 
external beam radiotherapy at 46-50,4 Gy, 1,8-2 Gy/day. 
Based on CT or PET CT if aortic nodes were demonstrated, 
extended external beam radiotherapy was performed. We 
boosted nodes or parametria if they were affected (60-68 Gy, 
2 Gy/day). After four weeks of treatment, patients received 
brachytherapy from 15 to 26 Gy in 3-6 fractions with 2D 
planification or 3D planification (n=28), with a total tumour 
dose between 85 and 90 Gy. Concurrent chemotherapy with 
weekly platin and in some cases oral fluoropirimidine was 
administrated. Overall treatment time did not exceed 8 
weeks. All patients completed surgery between 4-15 weeks 
after CCRT. 
 
Results: The median age was 52 years (range 30 and 77). 
Squamous cell carinoma was the most common subtype 
(81%). All patients received hysterectomy. 7 patients (12%) 
underwent lymphadenectomy. In global, 32 patients (54%) 
had a complete response, 20 (34%) a partial response and 7 
(12 %) patients had residual microscopic disease in the 
pathologic analysis. With a median follow up of 53 months 
(range from 2 to 128 months) overall survival was 85% and 
disease free survival 81% 
 
Conclusion: Our results show that CCRT followed by surgery 
gets excellents outcomes with acceptable toxicity and may 
reduce local recurrences. Besides it enables assessment of 
the pathological response. 
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Purpose or Objective: To quantify the magnitude of clinician 
uncertainty in GTV delineation for patients with recurrent 
gynaecological cancers. 
 
Material and Methods: GTV delineation uncertainty was 
retrospectively investigated in patients previously treated in 
our institution for centrally recurrent gynaecological cancer. 
In order to record clinician delineation uncertainty, clinicians 
were asked to draw 3 outlines per GTV; an inner GTV (GTV_I) 
corresponding to the innermost boundary the GTV is likely to 
have, an outer GTV (GTV_O)corresponding to the outmost 
boundary the GTV is likely to have and a clinical GTV (GTV_C) 
outlined in accordance with local treatment protocols. For 
GTV_C, each observer submitted a confidence score from 1 
to 5, with 1 being no confidence in drawn and 5 complete 
confidence. For each patient, the 3 GTV’s were delineated 
on a co-registered CT-MR, using a local rigid soft tissue 
registration, as well as on MR images only in order to identify 
how the co-registered CT information affects the decision 
process. Paired T Tests (p) were used to test for significance 
and Pearson correlation coefficient (r) for correlations. 
 
Results: To date, 18 recurrences from 17 patients were 
investigated by a single observer. For all 17 MR only contours 
and for 15 out of the 17 CT-MR contours, the GTV_O and 
GTV_C were identical. GTV_C ranged from 6.3 to 192.9cm3 
for CT-MR contours and from 5.5 to 180.1cm3 for the MR only 
contours, with a mean ± standard deviation of 53.3±44.7cm3 
and 39.3±40.4cm3 respectively. The reduction in GTV_I 
relative to GTV_C was 19.6±12.4cm3 (p<0.01) for CT-MR 
contours and 13.3±9.8cm3 (p<0.01) for MR only contours. For 
GTV_C, MR only contours were consistently smaller than CT-
MR contours by 14.0±11.4cm3 (p<0.01). For GTV_I, MR only 
contours were smaller for 13 out of the 17 cases, with 
differences of 7.9±7.7cm3 (p<0.01). The 3D difference in the 
centre of mass (COM) between GTV_O and GTV_C was 2±2mm 
for the CT-MR contours and 2±1mm for the MR only contours. 
Scoring of GTV_C was significantly lower (p<0.01) for CT-MR 
contours relative to MR only contours, with scores of 2.8±0.6 
and 3.6±0.7 respectively. 
 
Conclusion: Uncertainty exists in defining the boundary of 
the GTV for this patient cohort resulting in uncertainty in 
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both the volume and centre of the GTV. The process of using 
co-registering MR-CT images increases the uncertainty and 
leads to larger volumes when compared to GTV delineation 
using MR only. Data from additional observers will help 
quantify the magnitude of GTV delineation uncertainties. The 
limitation of having outlines from a single non-expert 
observer will be addressed in the final publication. 
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Purpose or Objective: To evaluate long-term clinical results 
after intensity modulated radiotherapy technique (IMRT) on 
vaginal vault in post-operative low-risk endometrial cancer 
patients. 
 
Material and Methods: Patients enrolled in two sequential 
trials (June 2006-October 2014) were analysed. A radiopaque 
methacrylate vaginal applicator was placed in the vagina. 
Patients were planned in supine position and immobilized 
using a vacuum cushion. Each patient was instructed to 
follow a protocol of controlled bladder filling and rectal 
emptying. Three radiopaque markers (1 mm diameter) fixed 
on the applicator allowed to improve visualization on portals 
imaging. Radiotherapy was delivered on the upper two thirds 
of the residual vagina (CTV), daily identified by the 
radiopaque markers. A 5 mm isotropic margin was added to 
the CTV in order to define the planning target volume (PTV). 
A 7 beams step and shoot IMRT technique was used by means 
of Plato Sunrise and Ergo++ treatment planning systems. 
25Gy/5Gy per fraction in the first trial and 30Gy/6Gy in the 
second one were the doses delivered to PTV. Toxicity was 
scored by the CTC-AE v.3.0 scale. 
 
Results: 23 patients (median age 63 years, range 49-88; stage 
IA: 69.6%, IB: 21.7%, II: 8.7%; grading G1: 3; G2: 17; G3: 3) 
were included in this analysis. Seven patients received 
25Gy/5Gy and 16 received 30 Gy/6Gy per fraction. Proctitis 
and dysuria were the most common toxicities. Twelve 
patients (52.2%) developed late mild toxicity (G2: 1 rectal 
bleeding and 1 atrophic skin with plaque lesions). The most 
common late toxicity was G1 vulvar telangiectasia (26%), 
while 3 patients developed G1 vaginal stenosis (Table 1). 
 
 
With a median follow-up of 52 months (range 4-103) no 
vaginal recurrence was observed (5-year local control: 100%), 
while 4 patients developed pelvic or distance relapse (5-year 
disease-free survival: 86.4%). Five-year overall survival was 
100%. 
 
Conclusion: Endovaginal brachytherapy studies reported 0-
5.2% late severe toxicity. Most toxicities were vaginal and 
urethral stenosis or rectal vaginal fistula, not observed in our 
study. In conclusion postoperative IMRT on vaginal vault 
showed promising clinical long-term results. 
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Purpose or Objective: The current study aims to evaluate 
the outcomes in patients treated with radical radiotherapy 
for cervical cancer who received external beam radiotherapy 
(EBRT) boost in place of intracavitary brachytherapy (ICBT).  
 
Material and Methods: We performed a multicenter 
retrospective study on the patients with cervical cancer 
treated with external beam boost as a substitution of ICBT 
during the period of January 2005 through October 2012 in 11 
participating radiation oncology centers in Korea. Treatment 
outcome, prognostic factor, and toxicity were evaluated.  
 
Results: Seventy-five patients were identified. The median 
age of the patients was 58 years (range, 33-92 years). The 
clinical stages were I in 6, II in 34, III in 18, and IVA in 17 
patients. Concurrent chemotherapy was performed to 64 
patients (85.3%). Radiation doses were median 46 Gy (range, 
40-54 Gy) for whole pelvis and 24 Gy (range, 9-35 Gy) for 
tumor boost. Three-dimensional radiotherapy (in 24 patients) 
or intensity-modulated radiotherapy (in 51 patients) was used 
for tumor boost. On images taken 3-6 months after 
radiotherapy, 46 patients showed complete response (CR), 24 
had partial response, and 2 were found to have progressive 
disease. The median follow-up time was 33 months. Disease 
progression was found in 30 patients (40.0%). Among these 
patients, 21 (28.0%) showed local progression with a median 
time to progression of 29 months (range, 3-101 months). The 
5-year local progression-free survival (LPFS) rate was 70.0%. 
On uni- and multivariate analyses, treatment response at 3-6 
